Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Long-term outcomes of Sleeping Beauty–generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas

Blood (2020) 135 (11): 862–865.

https://doi.org/10.1182/blood.2019002920

Published: 2020

Journal Articles

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

Blood (2020) 135 (11): 791–803.

https://doi.org/10.1182/blood.2019003988

Published: 2020

Includes: Supplemental data

Journal Articles

Bosutinib (SKI-606) Demonstrates Clinical Activity and Is Well Tolerated among Patients with AP and BP CML and Ph+ ALL.

C. Gambacorti-Passerini, MD, H. Kantarjian, MD, T. Bruemmendorf, MD, G. Martinelli, MD, M. Baccarani, MD, T. Fischer, MD, E.M. Pogliani, MD, B. Hewes, MD, A.D.G. Volkert, MD, N. Bardy-Bouxin, MD, J. Cortes, MD

Blood (2007) 110 (11): 473.

https://doi.org/10.1182/blood.V110.11.473.473

Published: 2007

Journal Articles

Efficacy and Safety of Bosutinib (SKI-606) among Patients with Chronic Phase Ph+ Chronic Myelogenous Leukemia (CML).

J. Cortes, MD, T. Bruemmendorf, MD, H. Kantarjian, MD, J. Khoury, MD, G. Rosti, MD, T. Fischer, MD, L. Tornaghi, MD, B. Hewes, MD, E.C. Martin, MD, C. Gambacorti-Passerini, MD

Blood (2007) 110 (11): 733.

https://doi.org/10.1182/blood.V110.11.733.733

Published: 2007

Journal Articles

Dasatinib (SPRYCEL®) 50mg or 70mg BID Versus 100mg or 140mg QD in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Resistant or Intolerant to Imatinib: Results of the CA180-034 Study.

Andreas Hochhaus, D.W. Kim, P. Rousselot, P.E. Dorlhiac-Llacer, J. Milone, S. Francis, E. Bleickardt, H. Kantarjian

Blood (2006) 108 (11): 166.

https://doi.org/10.1182/blood.V108.11.166.166

Published: 2006

Journal Articles

Patients with Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Targeted Therapy May Benefit from Prophylactic Measures Against Infections.

Gloria N. Mattiuzzi, MD, Jorge E. Cortes, MD, Stefan Faderl, MD, Maria E. Cabanillas, MD, Francis J. Giles, MD, Susan O’Brien, MD, Guillermo Garcia-Manero, MD, Hagop H. Kantarjian, MD

Blood (2006) 108 (11): 4483.

https://doi.org/10.1182/blood.V108.11.4483.4483

Published: 2006

Journal Articles

A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis or Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: The ‘START-L’ CA180015 Study.

Oliver G. Ottmann, G. Martinelli, H. Dombret, H. Kantarjian, A. Hochhaus, B. Simonsson, A. Aloe, A. Apanovitch, N. Shah

Blood (2005) 106 (11): 42.

https://doi.org/10.1182/blood.V106.11.42.42

Published: 2005

Journal Articles

Differences in Histone Acetylation Levels in CD34+ Cells between Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Correlation between Higher Levels of Histone 2B Acetylation and Survival in AML.

M. Gorre, I. Jilani, R. Chang, J. Bareng, H. Chan, M. Keating, H. Kantarjian, E. Estey, S. O’Brien, F. Giles, M. Albitar

Blood (2005) 106 (11): 2769.

https://doi.org/10.1182/blood.V106.11.2769.2769

Published: 2005

Journal Articles

4E-Binding Protein 1 (4E-BP1) in CD34+ Cells as Measured by Quantitative Flow Cytometry Is an Independent Prognostic Factor in Patients with Acute Myeloid Leukemia.

M. Gorre, I. Jilani, R. Chang, J. Bareng, H. Chan, M. Keating, H. Kantarjian, E. Estey, S. O’Brien, F. Giles, M. Albitar

Blood (2005) 106 (11): 2772.

https://doi.org/10.1182/blood.V106.11.2772.2772

Published: 2005

Journal Articles

Surface Antigens Identified by Antibody Microarray That Correlate with IgV H Mutational Status and ZAP70 Expression in CLL.

William G. Wierda, MD, PhD, S. Mulligan, MD, B. Shelvin, L. Belov, PhD, L. Rassenti, PhD, T. Kipps, MD, PhD, S. Lerner, MS, M. Thomas, PhD, H. Kantarjian, MD, M. Keating, MB, BS

Blood (2005) 106 (11): 2944.

https://doi.org/10.1182/blood.V106.11.2944.2944

Published: 2005

Journal Articles

Plasma Is a Reliable Source of mRNA for Testing IgVH Mutation Status in Patients with Chronic Lymphocytic Leukemia.

W. Ma, I. Jilani, M. Gorre, M. Keating, H. Chan, R. Tseng, H. Kantarjian, S. O’Brien, F. J. Giles, M. Albitar

Blood (2005) 106 (11): 2949.

https://doi.org/10.1182/blood.V106.11.2949.2949

Published: 2005

Journal Articles

Novel Quantitative Flow Cytometry-Based Signaling Assays Reveal a Potential Role for HSP90 Inhibitors in the Treatment of JAK2 Mutant-Positive Diseases.

M. Gorre, I. Jilani, H. Kantarjian, F. Giles, A. Hannah, M. Albitar

Blood (2005) 106 (11): 3526.

https://doi.org/10.1182/blood.V106.11.3526.3526

Published: 2005

Journal Articles

Measurement of HSP90 and HSP70 in CD34-Positive Cells: Lower Levels in Myelodysplastic Syndrome Than in Acute Myeloid Leukemia and Correlation with Clinical Behavior.

M. Gorre, I. Jilani, R. Chang, H. Chan, R. Urcia, M. Keating, H. Kantarjian, E. Estey, S. O’Brien, F. Giles, M. Albitar

Blood (2005) 106 (11): 3426.

https://doi.org/10.1182/blood.V106.11.3426.3426

Published: 2005

Journal Articles

Hypomethylation Therapy of Decitabine in Patients with Myelodysplastic Syndromes (MDS) Induces Apoptosis and Reduces Proliferation.

I. Jilani, H. Kantarjian, M. Gorre, J.-P. Issa, J. Bennett, A. Raza, F. Ravandi, H. Saba, M. Albitar

Blood (2005) 106 (11): 371.

https://doi.org/10.1182/blood.V106.11.371.371

Published: 2005

Journal Articles

Dasatinib (BMS-354825) in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: Update of a Phase I Study.

Charles L. Sawyers, H. Kantarjian, N. Shah, J. Cortes, R. Paquette, N. Donato, J. Nicoll, E. Bleickardt, T.-T. Chen, M. Talpaz

Blood (2005) 106 (11): 38.

https://doi.org/10.1182/blood.V106.11.38.38

Published: 2005

Journal Articles

Hemizygous/Homozygous and Heterozygous JAK2 Mutation Detected in Plasma of Patients with Myeloproliferative Diseases: Correlation with Clinical Behavior.

W. Ma, H. Kantarjian, I. Jilani, M. Gorre, F. Giles, J. Cortes, S. Verstovsek, S. O’Brien, M. Keating, M. Albitar

Blood (2005) 106 (11): 2593.

https://doi.org/10.1182/blood.V106.11.2593.2593

Published: 2005

Journal Articles

Weighted Prognostic Models for Survival in Untreated and Previously Treated Patients with CLL.

William G. Wierda, MD, PhD, S. OBrien, MD, X. Wang, MS, A. Ferrajoli, MD, S. Faderl, MD, D. Thomas, MD, F. Ravandi, MD, K. Do, PhD, H. Kantarjian, MD, S. Lerner, MS, M. Keating, MD

Blood (2005) 106 (11): 5012.

https://doi.org/10.1182/blood.V106.11.5012.5012

Published: 2005

Journal Articles

Discrepancy in Detecting Bcr-Abl Kinase Domain Mutations between Cells from Bone Marrow and Cells from Peripheral Blood, and Greater Concordance between Bone Marrow Cells and Plasma Free RNA.

W. Ma, H. Kantarjian, I. Jilani, M. Gorre, Ottmann, K. Bhalla, F. Giles, M. Albitar

Blood (2005) 106 (11): 4849.

https://doi.org/10.1182/blood.V106.11.4849.4849

Published: 2005

Journal Articles

Serum Beta-2 Microglobulin: The Universal Independent Prognostic Factor for Patients with CLL.

William G. Wierda, MD, PhD, X. Wang, MS, S. OBrien, MD, S. Faderl, MD, A. Ferrajoli, MD, D. Thomas, MD, F. Ravandi, MD, J. Cortes, MD, F. Giles, MD, C. Koller, MD, H. Kantarjian, MD, S. Lerner, MS, M. Keating, MB BS

Blood (2005) 106 (11): 5018.

https://doi.org/10.1182/blood.V106.11.5018.5018

Published: 2005

Journal Articles

Soluble Syndecan-1 (sCD138) Is an Independent Prognostic Factor in Patients with Chronic Lymphocytic Leukemia.

I. Jilani, M. Keating, W. William, A. Ferrajoli, H. Kantarjian, S. M. O’Brien, F. J. Giles, M. Albitar

Blood (2005) 106 (11): 713.

https://doi.org/10.1182/blood.V106.11.713.713

Published: 2005

NARROW

Long-term outcomes of Sleeping Beauty–generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

Bosutinib (SKI-606) Demonstrates Clinical Activity and Is Well Tolerated among Patients with AP and BP CML and Ph+ ALL.

Efficacy and Safety of Bosutinib (SKI-606) among Patients with Chronic Phase Ph+ Chronic Myelogenous Leukemia (CML).

Dasatinib (SPRYCEL®) 50mg or 70mg BID Versus 100mg or 140mg QD in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Resistant or Intolerant to Imatinib: Results of the CA180-034 Study.

Patients with Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Targeted Therapy May Benefit from Prophylactic Measures Against Infections.

A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis or Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: The ‘START-L’ CA180015 Study.

Differences in Histone Acetylation Levels in CD34+ Cells between Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Correlation between Higher Levels of Histone 2B Acetylation and Survival in AML.

4E-Binding Protein 1 (4E-BP1) in CD34+ Cells as Measured by Quantitative Flow Cytometry Is an Independent Prognostic Factor in Patients with Acute Myeloid Leukemia.

Surface Antigens Identified by Antibody Microarray That Correlate with IgV H Mutational Status and ZAP70 Expression in CLL.

Plasma Is a Reliable Source of mRNA for Testing IgVH Mutation Status in Patients with Chronic Lymphocytic Leukemia.

Novel Quantitative Flow Cytometry-Based Signaling Assays Reveal a Potential Role for HSP90 Inhibitors in the Treatment of JAK2 Mutant-Positive Diseases.

Measurement of HSP90 and HSP70 in CD34-Positive Cells: Lower Levels in Myelodysplastic Syndrome Than in Acute Myeloid Leukemia and Correlation with Clinical Behavior.

Hypomethylation Therapy of Decitabine in Patients with Myelodysplastic Syndromes (MDS) Induces Apoptosis and Reduces Proliferation.

Dasatinib (BMS-354825) in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: Update of a Phase I Study.

Hemizygous/Homozygous and Heterozygous JAK2 Mutation Detected in Plasma of Patients with Myeloproliferative Diseases: Correlation with Clinical Behavior.

Weighted Prognostic Models for Survival in Untreated and Previously Treated Patients with CLL.

Discrepancy in Detecting Bcr-Abl Kinase Domain Mutations between Cells from Bone Marrow and Cells from Peripheral Blood, and Greater Concordance between Bone Marrow Cells and Plasma Free RNA.

Serum Beta-2 Microglobulin: The Universal Independent Prognostic Factor for Patients with CLL.

Soluble Syndecan-1 (sCD138) Is an Independent Prognostic Factor in Patients with Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only